Valproic acid was originally developed to treat episodes of bipolar disorder and seizures (nervous system diseases) by hitting the mitochondrial enzymes succinate-semialdehyde dehydrogenase (ALDH5A1) and 4-aminobutyrate aminotransferase (ABAT). This evidence concerns the gene ABAT and nervous system disorder.